Research
Hormonal
Tirzepatide produced a mean weight loss of −7.14 kg in individuals without diabetes and −5.87 kg in individuals with type 2 diabetes (T2D).
Tirzepatide may be an effective option for weight management in both diabetic and non-diabetic obese adults.
GoodSupportsmedium confidence
The mean weight loss was − 7.14 kg in individuals without diabetes and − 5.87 kg in individuals with T2D.
Why this rating
The study is a prospective observational cohort study.
Source
Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study
Prabhat Kumar Agrawal et al. · Journal of Mid-life Health · 2026
DOI 10.4103/jmh.jmh_373_25
cohort · n=93
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →